Inclisiran

[anonymous]

All true. Direction from the top indicates even leadership doesn’t understand the buy and bill process.

There is one really good leader who knows a hell of a lot about this stuff, but he’s not at the top. One guess why he isn’t?

 

[anonymous]

There is one really good leader who knows a hell of a lot about this stuff, but he’s not at the top. One guess why he isn’t?

hahaha, seriously?

 

[anonymous]

Are the AdSoCs earning their sweet paycheck reaching out to all their Suite C contacts to put the necessary steps in place?

its not C suite contacts that will get this product utilized. It will come down to price, director of pharmacy and some KOL support within each system. Price most important. They already have 2 products on the market that do exactly what inclisiran does and they arent doing so well.

 

[anonymous]

Stupid Novartis fucks up again. Inclisiran price just got increased, these greedy bastards will get their money back

". . . these greedy bastards will get their money back".
This one didn't age well, did it?
Giving the product away for free for a year, a year delay at launch, and a complete refusal to incentivise the reps served them well, didn't it?
At this point, if they can get back 1/3 of what they paid for it they'll have to call it a win.

 

[anonymous]

". . . these greedy bastards will get their money back".
This one didn't age well, did it?
Giving the product away for free for a year, a year delay at launch, and a complete refusal to incentivise the reps served them well, didn't it?
At this point, if they can get back 1/3 of what they paid for it they'll have to call it a win.

They will never get their ROI.
Bad purchase. Overpriced purchase. Not gonna even hit $200 million in sales for 2024.

Sooner or later, someone smart will be hired and come and dump this dog of a drug. They will then write off the $9.7 billion as a loss over several years.

 

[anonymous]

They will never get their ROI.
Bad purchase. Overpriced purchase. Not gonna even hit $200 million in sales for 2024.

Sooner or later, someone smart will be hired and come and dump this dog of a drug. They will then write off the $9.7 billion as a loss over several years.

Three years in (actually, four). $200M in annual sales.
An embarrassment as bad as any this industry has ever seen for a medication that actually made it to market.
Measured against the $9.5B they spent on it, there is a chance it will be the worst launch in the history of pharma.
One thing to clear up - Leqvio is not a "dog".
The team they assembled to launch it (no B&B experience) was an unequivocal catastrophe, and they never really improved it much after they moved Duane's desk to another part of the building and shitcanned his little buddies, but it is unfair to blame this cesspool on Inclisiran.
When you hire idiots, dinosaurs and industry retreads to handle your $9.5B investment, you get results that look like this.
The fact that they overspent so recklessly to buy it & then decided to start cutting corners when hiring the launch team and paying the reps will always be a (professional) tragedy.

 

[anonymous]

Still no “outcomes” data doesn't help!